Related Experiment Video
Updated: Feb 28, 2026

Visualization of Vascular Ca2+ Signaling Triggered by Paracrine Derived ROS
Published on: December 21, 2011
TRPV4 calcium-permeable channel is a novel regulator of oxidized LDL-induced macrophage foam cell formation
Rishov Goswami1, Michael Merth1, Shweta Sharma1
1University of Maryland, Department of Nutrition and Food Science, College Park, MD 20742, USA.
Insights
Transient Receptor Potential Vanilloid 4 (TRPV4) channels mediate macrophage foam cell formation, a key process in atherosclerosis. Targeting TRPV4 may offer a novel therapeutic strategy for cardiovascular disease.
Area of Science:
- Cardiovascular Biology
- Cellular Mechanotransduction
- Atherosclerosis Research
Background:
- Cardiovascular disease is a leading cause of death, with atherosclerosis as the primary pathology.
- Macrophages play a central role in atherosclerosis by forming lipid-laden foam cells.
- The role of mechanical factors like matrix stiffness in macrophage function and atherosclerosis is emerging but mechanosensors are unknown.
Purpose of the Study:
- To identify the plasma membrane mechanosensor mediating oxidized low-density lipoprotein (oxLDL)-induced macrophage foam cell formation.
- To elucidate the mechanism by which TRPV4 regulates macrophage response to oxLDL and matrix stiffness.
- To investigate the therapeutic potential of targeting TRPV4 in atherosclerosis.
Main Methods:
- Utilized genetic ablation of TRPV4 and pharmacologic inhibition with a specific antagonist.
- Assessed macrophage foam cell formation in response to oxLDL and varying matrix stiffness.
- Investigated TRPV4 plasma membrane localization, CD36 expression, and oxLDL binding/uptake.
Main Results:
- Genetic or pharmacologic inhibition of TRPV4 blocked oxLDL-induced macrophage foam cell formation.
- TRPV4 deficiency prevented matrix stiffness-exacerbated foam cell formation.
- TRPV4 activity modulated oxLDL uptake, not binding, and its membrane localization was sensitive to matrix stiffness.
Conclusions:
- TRPV4 acts as a critical mechanosensor in macrophages, mediating oxLDL uptake and foam cell formation.
- TRPV4 is a novel regulator of macrophage response to mechanical cues in the context of atherosclerosis.
- Targeting TRPV4 presents a potential therapeutic strategy for treating atherosclerosis.
Abstract:
Cardiovascular disease is the number one cause of death in United States, and atherosclerosis, a chronic inflammatory arterial disease, is the most dominant underlying pathology. Macrophages are thought to orchestrate atherosclerosis by generating lipid-laden foam cells and by secreting inflammatory mediators. Emerging data support a role for a mechanical factor, e.g., matrix stiffness, in regulation of macrophage function, vascular elasticity, and atherogenesis. However, the identity of the plasma membrane mechanosensor and the mechanisms by which pro-atherogenic signals are transduced/maintained are unknown. We have obtained evidence that TRPV4, an ion channel in the transient receptor potential vanilloid family and a known mechanosensor, is the likely mediator of oxidized low-density lipoprotein (oxLDL)-dependent macrophage foam cell formation, a critical process in atherogenesis. Specifically, we found that: i) genetic ablation of TRPV4 or pharmacologic inhibition of TRPV4 activity by a specific antagonist blocked oxLDL-induced macrophage foam cell formation, and ii) TRPV4 deficiency prevented pathophysiological range matrix stiffness or scratch-induced exacerbation of oxLDL-induced foam cell formation. Mechanistically, we found that: i) plasma membrane localization of TRPV4 was sensitized to the increasing level of matrix stiffness, ii) lack of foam cell formation in TRPV4 null cells was not due to lack of expression of CD36, a major receptor for oxLDL, and iii) TRPV4 channel activity regulated oxLDL uptake but not its binding on macrophages. Altogether, these findings identify a novel role for TRPV4 in regulating macrophage foam cell formation by modulating uptake of oxLDL. These findings suggest that therapeutic targeting of TRPV4 may provide a selective approach to the treatment of atherosclerosis.
More Related Videos
Related Concept Videos
Inflammation
Coronary Artery Disease II: Pathophysiology
Receptor-mediated Endocytosis
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis I: Introduction

